Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shi-Dai Jin
Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
OncoTargets and Therapy
Oncology
Pharmacology
Related publications
The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients With Advanced Non-Small Cell Lung Cancer
Current Gerontology and Geriatrics Research
Gerontology
Geriatrics
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
JAMA - Journal of the American Medical Association
Medicine
Estrogen Receptor Β1 Activation Accelerates Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Oncology Reports
Medicine
Cancer Research
Oncology
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
The Association of Acquired T790M Mutation With Clinical Characteristics After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Cancer Research and Treatment
Cancer Research
Oncology
Impact of Epidermal Growth Factor Receptor Gene Expression Level on Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Patients Taking First-Line Epidermal Growth Factor Receptor–tyrosine Kinase Inhibitors
Tumor Biology
Medicine
Cancer Research
Overcoming Resistance to First/Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and ALK Inhibitors in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer
Therapeutic Advances in Medical Oncology
Oncology
